NES-ZIONA, Israel, Feb. 7, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that Dr. Abraham Havron, CEO of PROLOR, will give a corporate presentation at the Leerink Swann Hot Topics in Therapeutics: Roundtable Conference. The company has also been selected to participate in a panel on Emerging Platforms that includes Leerink Swann analysts. The conference will be held at the Roosevelt Hotel in New York City.
The PROLOR corporate presentation is scheduled for February 16, 2011 at 10:15 AM ET. The Emerging Platforms panel will be held the same day at 10:45 AM ET.
A live webcast of the company’s presentation will be available at the Investors’ section of
PROLOR’s website at www.prolor-biotech.com/?CategoryID=215, or at the Leerink Swann website at www.wsw.com/webcast/leerink20/pbth/. A replay of the presentation will be available for 90 days.
The Leerink Swann Roundtable Conference series spotlights the most promising healthcare and life sciences sectors and companies. These companies are selected to participate based on the recommendations of Leerink Swann’s financial professionals and medical experts from MEDACorp, a network of over 35,000 healthcare professionals that is a Leerink Swann partner.
For more information on the conference, visit http://www.leerink.com/about-us/news--events/current-conferences.aspx.
ABOUT PROLOR BIOTECH
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is in Phase II clinical development, and Factor IX, Factor VII, interferon beta and erythropoietin, which are in preclinical development, as well as an anti-obesity peptide and agents for atherosclerosis and rheumatoid arthritis. For more information, visit www.prolor-biotech.com.
PROLOR CONTACT: | MEDIA CONTACT: | |
Shai Novik, President | Barbara Lindheim | |
PROLOR Biotech, Inc. | GendeLLindheim BioCom Partners | |
Tel: +1 866 644-7811 | +1 212 918-4650 | |
Email: shai@prolor-biotech.com | blindheim@biocompartners.com | |
SOURCE PROLOR Biotech, Inc.
